Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi

S. Sacchi, Raffaella Marcheselli, A. Bari, G. Buda, A.L. Molinari, L. Baldini, D. Vallisa, M. Cesaretti, P. Musto, S. Ronconi, G. Specchia, Franco Silvestris, L. Guardigni, A. Ferrari, Annalisa Chiapella, A.M. Carella, A. Santoro, F. Di Raimondo, Luigi Marcheselli, Samantha Pozzi

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)e196-e199
JournalHaematologica
Volume101
Issue number5
DOIs
Publication statusPublished - 2016

Keywords

  • Efficacy
  • Indolent
  • Lenalidomide
  • Non-follicular lymphoma
  • Recurrent
  • Rituximab
  • Safety

Cite this

Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi. / Sacchi, S.; Marcheselli, Raffaella; Bari, A.; Buda, G.; Molinari, A.L.; Baldini, L.; Vallisa, D.; Cesaretti, M.; Musto, P.; Ronconi, S.; Specchia, G.; Silvestris, Franco; Guardigni, L.; Ferrari, A.; Chiapella, Annalisa; Carella, A.M.; Santoro, A.; Di Raimondo, F.; Marcheselli, Luigi; Pozzi, Samantha.

In: Haematologica, Vol. 101, No. 5, 2016, p. e196-e199.

Research output: Contribution to journalArticle

Sacchi, S, Marcheselli, R, Bari, A, Buda, G, Molinari, AL, Baldini, L, Vallisa, D, Cesaretti, M, Musto, P, Ronconi, S, Specchia, G, Silvestris, F, Guardigni, L, Ferrari, A, Chiapella, A, Carella, AM, Santoro, A, Di Raimondo, F, Marcheselli, L & Pozzi, S 2016, 'Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi', Haematologica, vol. 101, no. 5, pp. e196-e199. https://doi.org/10.3324/haematol.2015.139329
Sacchi, S. ; Marcheselli, Raffaella ; Bari, A. ; Buda, G. ; Molinari, A.L. ; Baldini, L. ; Vallisa, D. ; Cesaretti, M. ; Musto, P. ; Ronconi, S. ; Specchia, G. ; Silvestris, Franco ; Guardigni, L. ; Ferrari, A. ; Chiapella, Annalisa ; Carella, A.M. ; Santoro, A. ; Di Raimondo, F. ; Marcheselli, Luigi ; Pozzi, Samantha. / Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi. In: Haematologica. 2016 ; Vol. 101, No. 5. pp. e196-e199.
@article{0226335a99384b7aad64e8cc0e833b71,
title = "Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi",
keywords = "Efficacy, Indolent, Lenalidomide, Non-follicular lymphoma, Recurrent, Rituximab, Safety",
author = "S. Sacchi and Raffaella Marcheselli and A. Bari and G. Buda and A.L. Molinari and L. Baldini and D. Vallisa and M. Cesaretti and P. Musto and S. Ronconi and G. Specchia and Franco Silvestris and L. Guardigni and A. Ferrari and Annalisa Chiapella and A.M. Carella and A. Santoro and {Di Raimondo}, F. and Luigi Marcheselli and Samantha Pozzi",
note = "Cited By :1 Export Date: 16 March 2017 CODEN: HAEMA Correspondence Address: Sacchi, S.; Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio EmiliaItaly; email: stefano.sacchi@unimore.it References: McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Anti-Cd20 Monoclonal Antibody Therapy For Relapsed Indolent Lymphoma: Half Of Patients Respond To A Four-Dose Treatment Program (1998) J Clin Oncol, 16 (8), pp. 2825-2833; Sacchi, S., Pozzi, S., Marcheselli, L., Introduction of rituximab in front-line and salvage therapies has improved outcome of advancedstage follicular lymphoma patients (2007) Cancer, 109 (10), pp. 2077-2082; Flinn, I.W., Van Der Jagt, R., Kahl, B.S., Randomized trial of bendamustine- rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study (2014) Blood, 123 (19), pp. 2944-2952; Reddy, N., Hernandez-Ilizaliturri, F.J., Deeb, G., Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo (2008) Br J Haematol, 140 (1), pp. 36-45; Witzig, T.E., Wiernik, P.H., Moore, T., Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma (2009) J Clin Oncol, 27 (32), pp. 5404-5409; Zhang, L., Qian, Z., Cai, Z., Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo (2009) Am J Hematol, 84 (9), pp. 553-559; (2008) Classification of Tumors of Haematopoietic and Lymphoid Tissues, , World Health Organization, Lyon, France, IARC Press; Cheson, B.D., Horning, S.J., Coiffier, B., Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group (1999) J Clin Oncol, 17 (4), p. 1244; Thall, P.F., Simon, R.M., Estey, E.H., Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes (1995) Stat Med, 14 (4), pp. 357-379; Leonard, J.P., Sin-Ho Jung, S.H., Jeffrey, J., Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Al-liance) (2015) J Clin Oncol, 33 (31), pp. 3635-3640; Tuscano, J.M., Dutia, M., Chee, K., Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma (2014) Br J Haematol, 165 (3), pp. 375-381; Fowler, N.H., Davis, R.E., Rawal, S., Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: An open-label, phase 2 trial (2014) Lancet Oncol, 15 (12), pp. 1311-1318; Martin, P., Jung, S.H., Johnson, J.L., CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma (2014) J Clin Oncol, 32, p. 5s. , Abstract 8521; Buske, C., Towards a chemotherapy-free approach in indolent lymphoma (2014) Lancet Oncol, 15 (12), pp. 1281-1282",
year = "2016",
doi = "10.3324/haematol.2015.139329",
language = "English",
volume = "101",
pages = "e196--e199",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "5",

}

TY - JOUR

T1 - Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi

AU - Sacchi, S.

AU - Marcheselli, Raffaella

AU - Bari, A.

AU - Buda, G.

AU - Molinari, A.L.

AU - Baldini, L.

AU - Vallisa, D.

AU - Cesaretti, M.

AU - Musto, P.

AU - Ronconi, S.

AU - Specchia, G.

AU - Silvestris, Franco

AU - Guardigni, L.

AU - Ferrari, A.

AU - Chiapella, Annalisa

AU - Carella, A.M.

AU - Santoro, A.

AU - Di Raimondo, F.

AU - Marcheselli, Luigi

AU - Pozzi, Samantha

N1 - Cited By :1 Export Date: 16 March 2017 CODEN: HAEMA Correspondence Address: Sacchi, S.; Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio EmiliaItaly; email: stefano.sacchi@unimore.it References: McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Anti-Cd20 Monoclonal Antibody Therapy For Relapsed Indolent Lymphoma: Half Of Patients Respond To A Four-Dose Treatment Program (1998) J Clin Oncol, 16 (8), pp. 2825-2833; Sacchi, S., Pozzi, S., Marcheselli, L., Introduction of rituximab in front-line and salvage therapies has improved outcome of advancedstage follicular lymphoma patients (2007) Cancer, 109 (10), pp. 2077-2082; Flinn, I.W., Van Der Jagt, R., Kahl, B.S., Randomized trial of bendamustine- rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study (2014) Blood, 123 (19), pp. 2944-2952; Reddy, N., Hernandez-Ilizaliturri, F.J., Deeb, G., Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo (2008) Br J Haematol, 140 (1), pp. 36-45; Witzig, T.E., Wiernik, P.H., Moore, T., Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma (2009) J Clin Oncol, 27 (32), pp. 5404-5409; Zhang, L., Qian, Z., Cai, Z., Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo (2009) Am J Hematol, 84 (9), pp. 553-559; (2008) Classification of Tumors of Haematopoietic and Lymphoid Tissues, , World Health Organization, Lyon, France, IARC Press; Cheson, B.D., Horning, S.J., Coiffier, B., Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group (1999) J Clin Oncol, 17 (4), p. 1244; Thall, P.F., Simon, R.M., Estey, E.H., Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes (1995) Stat Med, 14 (4), pp. 357-379; Leonard, J.P., Sin-Ho Jung, S.H., Jeffrey, J., Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Al-liance) (2015) J Clin Oncol, 33 (31), pp. 3635-3640; Tuscano, J.M., Dutia, M., Chee, K., Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma (2014) Br J Haematol, 165 (3), pp. 375-381; Fowler, N.H., Davis, R.E., Rawal, S., Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: An open-label, phase 2 trial (2014) Lancet Oncol, 15 (12), pp. 1311-1318; Martin, P., Jung, S.H., Johnson, J.L., CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma (2014) J Clin Oncol, 32, p. 5s. , Abstract 8521; Buske, C., Towards a chemotherapy-free approach in indolent lymphoma (2014) Lancet Oncol, 15 (12), pp. 1281-1282

PY - 2016

Y1 - 2016

KW - Efficacy

KW - Indolent

KW - Lenalidomide

KW - Non-follicular lymphoma

KW - Recurrent

KW - Rituximab

KW - Safety

U2 - 10.3324/haematol.2015.139329

DO - 10.3324/haematol.2015.139329

M3 - Article

VL - 101

SP - e196-e199

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 5

ER -